Sunil Mehta - Emcure Pharmaceuticals Executive Director
EMCURE Stock | 1,421 33.45 2.41% |
Director
Sunil Mehta is Executive Director of Emcure Pharmaceuticals
Age | 61 |
Address | Plot No. P-1 and P-2, Pune, India, 411057 |
Phone | 91 20 3507 0033 |
Web | https://www.emcure.com |
Similar Executives
Found 14 records | DIRECTOR Age | ||
Rajiv Miglani | Rico Auto Industries | 60 | |
Doraiswami Balaji | Kingfa Science Technology | 62 | |
Akshali Shah | Parag Milk Foods | 32 | |
Narendra Mugatha | GACM Technologies Limited | N/A | |
Binaisha Zaveri | Tribhovandas Bhimji Zaveri | 42 | |
Jonna Rao | GACM Technologies Limited | 45 | |
AICWA BCom | COSMO FIRST LIMITED | 72 | |
Srinivas Maya | GACM Technologies Limited | 54 | |
Raashi Zaveri | Tribhovandas Bhimji Zaveri | 38 | |
Kaushalendra Verma | Rico Auto Industries | 56 | |
Samarth Kapur | Rico Auto Industries | 36 | |
Jayant Rao | Innova Captab Limited | 60 | |
Vinay Lohariwala | Innova Captab Limited | 48 | |
Pritam Shah | Parag Milk Foods | 54 |
Emcure Pharmaceuticals Leadership Team
Elected by the shareholders, the Emcure Pharmaceuticals' board of directors comprises two types of representatives: Emcure Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Emcure. The board's role is to monitor Emcure Pharmaceuticals' management team and ensure that shareholders' interests are well served. Emcure Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Emcure Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Chetan Sharma, Company Officer | ||
Vikas Thapar, Strategy Development | ||
Rajesh Nair, Executive Resources | ||
Satish Mehta, MD CEO | ||
Samit Mehta, President Director | ||
Naveen Soni, Director Relations | ||
Mukund Gurjar, Chief Director | ||
Namita Thapar, Executive Director | ||
Tajuddin Shaikh, Chief Officer | ||
Sunil Mehta, Executive Director |
Emcure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Emcure Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Profit Margin | 0.07 % | ||||
Operating Margin | 0.13 % | ||||
Current Valuation | 295.8 B | ||||
Shares Owned By Insiders | 86.77 % | ||||
Shares Owned By Institutions | 3.53 % | ||||
Price To Book | 9.39 X | ||||
Price To Sales | 3.92 X | ||||
Revenue | 69.17 B | ||||
EBITDA | 12.05 B | ||||
Book Value Per Share | 162.97 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Emcure Stock
Emcure Pharmaceuticals financial ratios help investors to determine whether Emcure Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Emcure with respect to the benefits of owning Emcure Pharmaceuticals security.